Sign Out
Individuals with known hypersensitivity to any constituent of botulinum toxin product: Patients with myasthenia gravis or Eaton-Lambert syndrome; presence of infection at the proposed injection site(s). The recommended dosages and frequencies of administration of NABOTA should not be exceeded.
Botulinum toxin for treatment of urinary incontinence due to neurogenic detrusor overactivity is also contraindicated in patients who have acute urinary tract infection and in patients with acute urinary retention who are not routinely performing clean intermittent self-catheterization (CIC).
